Literature DB >> 27774121

Therapeutic Potential of Smurf-1 Inhibitors for the Treatment of Pulmonary Arterial Hypertension (PAH).

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2016        PMID： 27774121      PMCID： PMC5066148          DOI： 10.1021/acsmedchemlett.6b00326

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

1.  Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension.

Authors:  Koko Murakami; Rajamma Mathew; Jing Huang; Reza Farahani; Hong Peng; Susan C Olson; Joseph D Etlinger
Journal:  Exp Biol Med (Maywood)       Date:  2010-07

Review 2.  Pharmaceutical perspectives of HECT-type ubiquitin ligase Smurf1.

Authors:  Yu Cao; Lingqiang Zhang
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 3.  A Smurf1 tale: function and regulation of an ubiquitin ligase in multiple cellular networks.

Authors:  Yu Cao; Lingqiang Zhang
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 4.  Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.

Authors:  Rajiv D Machado; Laura Southgate; Christina A Eichstaedt; Micheala A Aldred; Eric D Austin; D Hunter Best; Wendy K Chung; Nicola Benjamin; C Gregory Elliott; Mélanie Eyries; Christine Fischer; Stefan Gräf; Katrin Hinderhofer; Marc Humbert; Steven B Keiles; James E Loyd; Nicholas W Morrell; John H Newman; Florent Soubrier; Richard C Trembath; Rebecca Rodríguez Viales; Ekkehard Grünig
Journal:  Hum Mutat       Date:  2015-10-12       Impact factor: 4.878
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.